secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2026-08-03T20:24:23+00:00
Accession:  0001193125-26-330644
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Q2 CASGEVY revenue $76M (+151% YoY); FDA expands approval to children 2+
-------------------------------------------------------------------------------

- CASGEVY Q2 revenue $76M, up 78% QoQ and 151% YoY; FDA approved for children 2+ with SCD/TDT, adding ~5,500 eligible patients.
- Initiated Phase 1 trials for CTX340 (refractory hypertension) and CTX460 (alpha-1 antitrypsin deficiency) using in vivo LNP delivery.
- Cash $2.36B at June 30, 2026, up from $1.98B at Dec 31, 2025, boosted by $585M convertible note issuance.
- Net loss narrowed to $91.2M from $208.5M in Q2 2025, driven by lower acquired IPR&D and higher CASGEVY revenue.
- Phase 1b update for CTX310 (ANGPTL3) expected at ESC Congress Aug 28; Phase 2 for CTX611 (FXI siRNA) ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000119312526330644/0001193125-26-330644-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000119312526330644/crsp-20260803.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-330644

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer